Project Grant R43AI138868

The Project Grant award R21CA282561 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to test the ability of the CSP7 peptide to inhibit radiation-induced lung injury (RILI) and pulmonary fibrosis (RIPF) in mice. The $219,024 award, spanning July 1, 2025 to June 30, 2027, will support research conducted by the University of Texas Health Science Center at Tyler. Specifically, the project will evaluate whether CSP7 can prevent the development of RILI and RIPF, as...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to develop the compound CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. Cytoagents is conducting a Phase 1b clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of CTO1681 in reducing CRS and immune effector cell-associated neurotoxicity...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), will fund Synthis Therapeutics, Inc. to develop a new immune cell-targeted TGF-beta therapy called SYN101. The goal is to reverse TGF-beta-mediated immune suppression in cancer patients, improving the efficacy of existing immunotherapies. The $3,157,784 award will support in vivo efficacy, safety, and pharmacokinetic studies of SYN101 in preclinical models. This includes testing the...

The U.S. National Institutes of Health (NIH) awarded a $552,787 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Old Dominion University (ODU) and its research foundation, Odurf, to develop YK-4-250, a novel radiation mitigator for gastrointestinal acute radiation syndrome (GI-ARS). The research aims to investigate the mechanisms of the renin-angiotensin system and reactive oxygen species signaling through the AT1 receptor to mitigate GI-ARS. Key objectives...

This Project Grant award under the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $662,516 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on imaging-guided drug delivery for safer and more effective chemoradiotherapy. The project aims to evaluate how fractionated radiation affects the tumor microenvironment and passive drug delivery, and test whether long-circulating chemotherapy can synergistically...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to SRI International provides $401,125 in funding to quantify the association between genetic factors and radiation sensitivity in cancer patients. The research aims to identify germline genetic variants and gene expression patterns that contribute to individual differences in radiation response. The goal is to develop a predictive screening platform to optimize radiation dosing and mitigate...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This Cooperative Agreement award, with a total funding amount of $1,072,951, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the award is to conduct a randomized clinical trial evaluating the efficacy and safety of low-dose versus moderate-dose busulfan conditioning regimens for hematopoietic cell transplantation in infants with severe combined immunodeficiency (SCID) due...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $678,101 to The Regents of the University of California, San Francisco to conduct preclinical validation of a novel radioimmunotherapy (RIT) targeting the active conformation of integrin beta-2 (AITGB2) for the treatment of acute myeloid leukemia (AML). The research aims to evaluate the RIT's preclinical efficacy, toxicity, and combination efficacy with standard AML therapy...